Skip to content
RNAWiki

Glatiramer Acetate

  • Prescription medicine
  • Given by a clinician
  • Identity checked
  • Sources last checked 2026-09-04

This page shows what was measured, who it was measured in, and what that does not settle.

What Glatiramer Acetate does in the body

Glatiramer Acetate Injection is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.

From the FDA-approved label: The mechanism(s) by which glatiramer acetate exerts its effects in patients with MS are not fully understood. However, glatiramer acetate is thought to act by modifying immune processes that are believed to be responsible for the pathogenesis of MS. This hypothesis is supported by findings of studies that have been carried out to explore the pathogenesis of experimental autoimmune encephalomyelitis, a condition induced in animals through immunization against central nervous system derived material containing myelin and often used as an experimental animal model of MS.

Why people take it. Glatiramer Acetate Injection is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.

What happened in people

RNAWiki has not yet published a reviewed conclusion for this use.

A fixed RNAWiki sentence

Where this came from

Wording RNAWiki always uses, not a finding about this substance.

No reviewed claim names a result for any goal on this record.

No source is stored against this line.

The limit that matters most

Not recorded.

Where it acts
Not recorded.
Kind of result
No result is published, so no kind of result applies yet
Supervision
Professional supervision is normally required. A regulator classifies this substance in a way that restricts how it is supplied.

What the registries record it as

  • The substance registry classes this as polymer.

    FDA substance registry · 5M691HL4BO · read 2026-08-29

Where each sentence above came from

The use the label states, quoted from it. No plain-language version of this sentence has been written.

The use the label states, quoted from it. It is written for a clinician, not for a reader without medical training.

No statement of the main limit is recorded.

The four opening statements run to 159 words.

Words this page uses

Four words worth knowing first

Chosen from what this page shows, with each one explained before the word it depends on.

Biomarker

A biomarker is a number from a test that stands in for something about health.

A picture of it, and where the picture fails

A biomarker is like a fuel gauge.

Where that stops being true. A gauge is wired to the tank. Many biomarkers are only loosely tied to health.

What people get wrong. A better number is read as a better life. Several medicines improved a number and helped nobody.

A measurable indicator used as a substitute for a clinical outcome of interest.

Placebo

A placebo is a dummy treatment given so the real one can be compared with it.

A picture of it, and where the picture fails

A placebo is like a blank control in an experiment.

Where that stops being true. A blank does nothing. People given a placebo often do get better.

What people get wrong. A placebo effect is read as imaginary. The improvement is measured and real.

An inactive intervention matched in appearance to the test intervention, used to control for non-specific effects.

Comparator

A comparator is whatever the treatment was measured against.

A picture of it, and where the picture fails

It is like the other runner in a race.

Where that stops being true. A race has one winner. A study can show both arms improved.

What people get wrong. Results are read without asking what the other group got. Beating nothing is not beating a treatment.

The control condition against which the experimental intervention is assessed.

What happened in peopleRead from sources, not yet reviewed

What happened in people

Each card is one study: the exact question it asked, who was in it, and whether it showed what it set out to show.

Hazard ratio for relapses

The study did not show it

Who was studied
NCT00099502
How many people
2244
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated

What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.

The limits of this study, and where it came from

Main limit. No limitation is recorded for this study.

How far it carries. This study is recorded from the curated record, not from the registry match.

Form and route. Subcutaneous

Interval reported. Not recorded in this summary

Written into the record, not signed off as a reviewed claim.

  • openFDA Drugs@FDA · a recorded source, not a stored snapshot
  • openFDA NDC Directory · a recorded source, not a stored snapshot
  • openFDA SPL label · a recorded source, not a stored snapshot
  • FDA label (openFDA SPL) · a recorded source, not a stored snapshot

Flu-like-syndrome

The study did not show it

Who was studied
NCT00459667
How many people
1420
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated

What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.

The limits of this study, and where it came from

Main limit. No limitation is recorded for this study.

How far it carries. This study is recorded from the curated record, not from the registry match.

Form and route. Subcutaneous

Interval reported. Not recorded in this summary

Written into the record, not signed off as a reviewed claim.

  • openFDA Drugs@FDA · a recorded source, not a stored snapshot
  • openFDA NDC Directory · a recorded source, not a stored snapshot
  • openFDA SPL label · a recorded source, not a stored snapshot
  • FDA label (openFDA SPL) · a recorded source, not a stored snapshot

Annualized Relapse Rate

The study did not show it

Who was studied
NCT00451451
How many people
1417
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated

What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.

The limits of this study, and where it came from

Main limit. No limitation is recorded for this study.

How far it carries. This study is recorded from the curated record, not from the registry match.

Form and route. Subcutaneous

Interval reported. Not recorded in this summary

Written into the record, not signed off as a reviewed claim.

  • openFDA Drugs@FDA · a recorded source, not a stored snapshot
  • openFDA NDC Directory · a recorded source, not a stored snapshot
  • openFDA SPL label · a recorded source, not a stored snapshot
  • FDA label (openFDA SPL) · a recorded source, not a stored snapshot

Total Number of Confirmed Relapses During the Placebo Controlled (PC) Treatment Period Estimated by Negative Binomial Regression

The study did not show it

Who was studied
NCT01067521
How many people
1404
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated

What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.

The limits of this study, and where it came from

Main limit. No limitation is recorded for this study.

How far it carries. This study is recorded from the curated record, not from the registry match.

Form and route. Subcutaneous

Interval reported. Not recorded in this summary

Written into the record, not signed off as a reviewed claim.

  • openFDA Drugs@FDA · a recorded source, not a stored snapshot
  • openFDA NDC Directory · a recorded source, not a stored snapshot
  • openFDA SPL label · a recorded source, not a stored snapshot
  • FDA label (openFDA SPL) · a recorded source, not a stored snapshot

The Rate of Confirmed Relapses During the Double-blind Phase (12 Months).

The study did not show it

Who was studied
NCT00337779
How many people
1155
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated

What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.

The limits of this study, and where it came from

Main limit. No limitation is recorded for this study.

How far it carries. This study is recorded from the curated record, not from the registry match.

Form and route. Subcutaneous

Interval reported. Not recorded in this summary

Written into the record, not signed off as a reviewed claim.

  • openFDA Drugs@FDA · a recorded source, not a stored snapshot
  • openFDA NDC Directory · a recorded source, not a stored snapshot
  • openFDA SPL label · a recorded source, not a stored snapshot
  • FDA label (openFDA SPL) · a recorded source, not a stored snapshot

Time to 24-week Confirmed Expanded Disability Status Scale (EDSS) Progression

The study did not show it

Who was studied
NCT00297232
How many people
1094
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated

What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.

The limits of this study, and where it came from

Main limit. No limitation is recorded for this study.

How far it carries. This study is recorded from the curated record, not from the registry match.

Form and route. Subcutaneous

Interval reported. Not recorded in this summary

Written into the record, not signed off as a reviewed claim.

  • openFDA Drugs@FDA · a recorded source, not a stored snapshot
  • openFDA NDC Directory · a recorded source, not a stored snapshot
  • openFDA SPL label · a recorded source, not a stored snapshot
  • FDA label (openFDA SPL) · a recorded source, not a stored snapshot
What we know
RNAWiki holds 6 written-up human studies for this substance, each with the question it asked.
How we know it
Each card names the study, the number of people and what the study set out to measure.
What this does not prove
These summaries were written by a person and have not been signed off as reviewed claims.
Why it matters
A study that failed is as informative as one that worked, and both are here.
What we still do not know
No reviewed claim exists, so no exact population, effect size or interval is published yet.

What is missing or unclearRead from sources, not yet reviewed

Were people like you studied?

RNAWiki cannot tell whether a study fits you. It can show who was in it, and where the result stops carrying.

Who was studied

People similar to this profile were included.

  • Glatiramer acetate injection is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.

Who is missing from the studies

  • Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.

What the label states about particular groups

  • On pediatric, the label states: “The safety and effectiveness of Glatiramer Acetate Injection have not been established in patients under 18 years of age.”

    US prescribing information · 707a64ef-964e-44a3-8a0f-fcc2eb5b1af2 · read 2026-08-30

  • On older people, the label states: “Glatiramer Acetate Injection has not been studied in elderly patients.”

    US prescribing information · 707a64ef-964e-44a3-8a0f-fcc2eb5b1af2 · read 2026-08-30

  • On people who are pregnant, the label states: “Risk Summary Available data from pharmacovigilance and published observational studies over decades of use with glatiramer acetate during pregnancy have not identified a drug-associated risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes ( see Data ).”

    US prescribing information · 707a64ef-964e-44a3-8a0f-fcc2eb5b1af2 · read 2026-08-30

  • On people who are breastfeeding, the label states: “Risk Summary There are no data on the presence of glatiramer acetate in human milk.”

    US prescribing information · 707a64ef-964e-44a3-8a0f-fcc2eb5b1af2 · read 2026-08-30

Where the result stopped carrying

  • This is a scope explorer, not a diagnosis engine.
  • It shows who was studied so you can see whether people similar to you were included.

RNAWiki cannot tell whether a study fits you. It can show who was in it.

What it would be like to takeRead from sources, not yet reviewed

Why it might seem to do nothing

A real effect and a noticed effect are different things. These are the recorded reasons the two come apart.

It was studied in different people

The people in the studies were not much like the reader.

On this record: Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.

The evidence may simply be wrong

Small early studies often do not hold up.

On this record: RNAWiki has not yet published a reviewed conclusion for this use.

Other reasons RNAWiki checked and found nothing for (11)
It was studied for a different goal
The studies measured something else entirely. Nothing in this record points to this reason.
A different form was studied
The studied form is not the form on the shelf. Nothing in this record points to this reason.
There was nothing to correct
Where a level is already normal, topping it up may change nothing. Nothing in this record points to this reason.
Something else had to happen too
In the studies it was paired with training, a diet or another treatment. Nothing in this record points to this reason.
The change is too small to feel
A real change can still sit below what a person notices. Nothing in this record points to this reason.
Day-to-day swing hides it
Sleep, food, stress and time of day move most numbers more than this would. Nothing in this record points to this reason.
Not enough time yet
The studies ran longer than the person has waited. Nothing in this record points to this reason.
It was not taken as studied
Missed days change the result, and studies count them. Nothing in this record points to this reason.
Something else changed at the same time
Two changes at once cannot be told apart afterwards. Nothing in this record points to this reason.
The product may not be what it says
Contents of a sold product are not always what the label states. Nothing in this record points to this reason.
No recorded reason
RNAWiki has nothing stored that would explain it. Nothing in this record points to this reason.

None of these is a reason to take more. Taking more is not a step this page ever suggests.

What it would be like to takeRead from sources, not yet reviewed

What taking it involves

The recorded facts about getting hold of it and using it. Nothing here is a suggestion about what you should do.

How it is supplied

Given by a clinician

Quoted from a source

Where this came from

Copied from a source RNAWiki stored, with the source named.

Read from the recorded approval status.

No source is stored against this line.

Form and route

Subcutaneous

Source-linked record

Where this came from

A person wrote this into the record with the study named beside it. No reviewer has signed it off.

The form and route recorded on this substance.

No source is stored against this line.

Who oversees it

Professional supervision is normally required. A regulator classifies this substance in a way that restricts how it is supplied.

Quoted from a source

Where this came from

Copied from a source RNAWiki stored, with the source named.

Suppression classes recorded: S6.

No source is stored against this line.

What is in the pack

Sold as injectable, for solution, injection, solution, given by the subcutaneous route.

Source-linked record

Where this came from

A person wrote this into the record with the study named beside it. No reviewer has signed it off.

Recorded notes on how this is sold and what that means for what is in the pack.

No source is stored against this line.

Where it is registered

Regulatory records are listed in the technical disclosure at the foot of this page.

Counted from records

Where this came from

A count of rows RNAWiki holds. It describes our records, not your body.

Register entries are stored per jurisdiction and shown with their dates.

No source is stored against this line.

Why people stop

Not recorded.

Nothing recorded

Where this came from

RNAWiki holds nothing here and says so rather than guessing.

No record of why people stopped taking it is stored for this substance.

No source is stored against this line.

What it would be like to takeNothing found in the sources checked

What can go wrong

Sorted by where each line came from. A regulator's label and a report somebody sent in are not the same kind of fact.

Nothing found in the sources checked

No harm is recorded against this substance in the sources RNAWiki checked. Finding nothing is not the same as showing there is nothing.

The sources listed were searched and held nothing. That is not the same as nothing existing.

Over a long time. No completed tested study window is recorded, so long-term effects are not established by the registry record.

Groups the studies covered thinly. Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.

What is missing or unclearRead from sources, not yet reviewed

Does the exact form matter?

Evidence belongs to the exact thing that was tested. A different salt, a different mixture or a different preparation is a different question.

The form that was studied

Subcutaneous

Source-linked record

Where this came from

A person wrote this into the record with the study named beside it. No reviewer has signed it off.

The form used in the studies cited on this page.

No source is stored against this line.

What is sold

Not recorded.

Nothing recorded

Where this came from

RNAWiki holds nothing here and says so rather than guessing.

Nothing further is recorded about which forms are sold.

No source is stored against this line.

What is recorded as being sold

  • 27 products list this as an active ingredient in the United States drug directory. 27 of them contain it and nothing else.

    FDA National Drug Code directory · 11797-764 · read 2026-08-29

  • They are sold as injection, injection, solution and powder, taken subcutaneous.

    FDA National Drug Code directory · 11797-764 · read 2026-08-29

  • 13 published labels name it as an active ingredient. 13 of them describe this substance alone, which is where its own label text on this page comes from.

    US prescribing information · 707a64ef-964e-44a3-8a0f-fcc2eb5b1af2 · read 2026-08-29

  • Those labels are classed as human prescription drug.

    US prescribing information · 707a64ef-964e-44a3-8a0f-fcc2eb5b1af2 · read 2026-08-29

  • Glatiramer Acetate is subcutaneous at 3 DOSAGE FORMS AND STRENGTHS Injection: 20 mg per mL in a single-dose, prefilled syringe with a white plunger., recorded as fda label in effect 2026-01-15 in the United States.

    US prescribing information · 707a64ef-964e-44a3-8a0f-fcc2eb5b1af2 · read 2026-08-30

  • Recorded price in US: 42.68157–91.0725 USD per one millilitre, across 8 priced products whose strengths and pack forms differ, as of 2026-08-26, paid by retail pharmacies buying the product, as surveyed by the Centers for Medicare & Medicaid Services. It is not a list price, an insurance price, or what anyone pays at a counter..

    Recorded source · 2026-08-26 · read 2026-08-28

Evidence carries across two names for one substance. It does not carry across a salt, a mirror form or a mixture.

What it would be like to takeRead from sources, not yet reviewed

What you could measure

This one is decided with a clinician, so this section holds questions to ask rather than a plan to run.

Self-experiment planning is not offered for a prescription or clinician-supervised medicine. The questions below are for a clinician or pharmacist.

Questions worth asking

  • Which of the trials of Glatiramer Acetate studied people like me?
  • What was measured, and for how long?
  • Was the result a laboratory value or a health outcome?
  • What would we watch for, and when would we stop?

Tracking can show whether something changed for you. It cannot show what caused it.

RNAWiki records evidence. It does not say whether this substance is right for you.

What is missing or unclearRead from sources, not yet reviewed

What nobody knows yet

Open questions, each with why it is open and what would close it.

Missing populations

Which groups were under-represented in the studies has not been recorded.

Why it matters. Recorded by the evidence model as a gap on this record.

What would answer it

A study that measures it, and a reviewer to sign it off.

Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.

Missing long-term data

No completed tested study window is recorded.

Why it matters. Recorded by the evidence model as a gap on this record.

What would answer it

A study that measures it, and a reviewer to sign it off.

Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.

No reviewed conclusion

RNAWiki has not yet published a reviewed conclusion for this use.

Why it matters. Recorded by the evidence model as a gap on this record.

What would answer it

A study that measures it, and a reviewer to sign it off.

Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.

Missing interaction studies

No interaction was found in the registers checked. Not finding one is not the same as showing there is none.

Why it matters. Recorded by the evidence model as a gap on this record.

What would answer it

A study that measures it, and a reviewer to sign it off.

Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.

Formulation uncertainty

Several salts, forms or products of Glatiramer Acetate are recorded. Results from one form may not transfer to another.

Why it matters. Recorded by the evidence model as a gap on this record.

What would answer it

A study that measures it, and a reviewer to sign it off.

Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.

Mechanism not reviewed

No reviewed mechanism story exists for this substance.

Why it matters. Recorded by the evidence model as a gap on this record.

What would answer it

A study that measures it, and a reviewer to sign it off.

Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.

What happened in peopleRead from sources, not yet reviewed

Check any of this yourself

Every line above traced back to the study it came from. This is the technical layer, and the vocabulary changes here.

Where else this substance is registered

FDA substance identifier (UNII)
5M691HL4BO
RxNorm concept
1487361

Checks this page had to pass

  • Passed

    Identity resolved

    no open identity hold

  • Passed

    No unresolved merge across substance families

    no quarantine open

  • Passed

    Every public sentence names a source

    The opening statement carries the origin: Quoted from a stored source.

  • Not passed

    Trial roles classified for highlighted evidence

    No registered study is classified as testing this substance.

  • Passed

    No internal keys in reader text

    enforced by the copy-contract test over the rendered page

  • Passed

    Safety mode resolved

    Suppression classes recorded: S6.

  • Passed

    Canonical metadata present

    slug and display name present

What is missing or unclearRead from sources, not yet reviewed

How this medicine reached us

Kept near the foot of the page. A historical event moves up only when it changes something about this substance today.

What the approval register records

  • 11 approved applications cover products containing this substance. The earliest was NDA020622, approved 19961220 to TEVA PHARMS USA.

    Drugs@FDA application register · NDA020622 · read 2026-08-29

  • Marketing status on the register: discontinued and prescription.

    Drugs@FDA application register · NDA020622 · read 2026-08-29

  • The earliest marketing start date recorded for a listed product is 20080428.

    FDA National Drug Code directory · 11797-764 · read 2026-08-29

What is missing or unclearRead from sources, not yet reviewed

What to learn next

Ordered by what would most change how you read this page, starting with what is easiest to misunderstand.

This order is fixed in code and does not count clicks or time on the page.

What is not here

9 questions this page could not answer

These sections were prepared and left out because there was nothing to put in them. They are listed rather than hidden, so the gaps in this record are visible.

  • What was measured, goal by goal — found nothing in the sources checked.
  • How close this is to real life — found nothing in the sources checked.
  • The path through the body — found nothing in the sources checked.
  • Felt, measured, or meaningful — found nothing in the sources checked.
  • How long anything takes — found nothing in the sources checked.
  • What it may clash with — found nothing in the sources checked.
  • Other ways to the same goal — found nothing in the sources checked.
  • Claims that go past the evidence — found nothing in the sources checked.
  • What changed on this page — found nothing in the sources checked.

The record as stored

The full record, for auditing

Everything above is built from what is below. This layer keeps the technical vocabulary, record identifiers and every stored row, so a reader who wants to check the page can.

Recorded evidence blocks (8)

On the Glatiramer Acetate label: indicated for what?

"Glatopa is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. Glatopa is indicated for the treatment of relapsing-forms of multiple sclerosis (MS), to include clinically…": indications and usage on Glatiramer Acetate's label. DailyMed label · 028fdf0e-2340-407b-bcd8-5a99accdddbf · 2025-03-27

66 registered trials of Glatiramer Acetate — at which phases?

Registered studies posting no result
34 of 66

66 registered studies of Glatiramer Acetate: 20 phase3, 16 phase2, 16 phase4, 9 na or unstated, 4 na, 3 phase1. CLINICALTRIALS_SNAPSHOT · 2026-09-01

202 with a PubMed record

Show the evidence
  • phase3
    20
  • phase2
    16
  • phase4
    16
  • na or unstated
    9
  • na
    4
  • phase1
    3
7 more recorded rows
  • completed
    44
  • unknown
    9
  • terminated
    8
  • active not recruiting
    2
  • recruiting
    1
  • suspended
    1
  • withdrawn
    1

recorded 2026-09-01 · last checked 2026-09-04

9 of Glatiramer Acetate's trials stopped: safety, accrual/recruitment, other?

safety (3), accrual/recruitment (4) and other (2): Glatiramer Acetate's stop wording, clustered. CLINICALTRIALS_SNAPSHOT · 2026-09-01

"Slow enrollment decreased sample size No unexpected safety issues."; 9 of 66 registered studies

Show the evidence

Trial

  • NCT00202995
    terminated; "Slow enrollment decreased sample size No unexpected safety issues."
  • NCT00203047
    terminated; "Slow enrollment decreased sample size; No unexpected safety issues."
  • NCT00398528
    terminated; "rate of enrollment"
  • NCT00541333
    suspended; "Reviewing data"
  • NCT01058005
    terminated; "Due to significantly slower than expected enrollment, the Sponsor decided to terminate the study."
  • NCT01633112
    terminated; "slow recruitment"
3 further recorded trials
  • NCT01963611
    terminated; "Study was terminated based on sponsor discretion."
  • NCT03368664
    terminated; "Enrolment formally closed earlier than planned due to recruitment challenges."
  • NCT04079088
    withdrawn; "Decision to discontinue BIIB061 program was based on lack of stronger preclinical effects of BIIB061 on remyelination relative to opicinumab, that showed limited clinical efficacy in phase 2 clinical studies. This was not related to safety…"

recorded 2026-09-01 · last checked 2026-09-04

Human studies of Glatiramer Acetate used Copaxone 20 mg injected SQ every day (glatiramer acetate) — over how long?

studies of Glatiramer Acetate used the recorded amount. ClinicalTrials.gov · 2026-09-01

9 recorded entries; human; also "Copaxone 20 mg injected SQ every day (glatiramer acetate)", "glatiramer acetate 20 mg", "glatiramer acetate 40 mg"

Show the evidence

human

  • NCT00176592
    Copaxone 20 mg injected SQ every day (glatiramer acetate)
  • NCT00202982
    glatiramer acetate 20 mg
  • NCT00202982
    glatiramer acetate 40 mg
  • NCT00203073
    glatiramer acetate 20 mg, with mitoxantrone
  • NCT00326625
    40 mg glatiramer acetate
  • NCT00337779
    Glatiramer Acetate (GA) 40 mg
3 more recorded rows
  • human NCT01167426
    Glatiramer Acetate 20 mg/0.5 mL
  • human NCT01167426
    Glatiramer acetate 20 mg/0.5 mL
  • human NCT01963611
    Copaxone 20 mg

recorded 2026-09-01 · last checked 2026-09-04

Which 16 trials of Glatiramer Acetate posted no result?

Posted no result
16 of 16 completed trials
Registrations
NCT00203073, NCT00202982, NCT00220922, NCT00239993, NCT00203112 and NCT00240032, and 10 more
Completion dates
oldest 2005-04; newest 2024-03-31
Show the evidence

Trial

  • NCT00203073
    2005-04
  • NCT00202982
    2005-09
  • NCT00220922
    2006-02
  • NCT00239993
    2006-02
  • NCT00203112
    2006-07
  • NCT00240032
    2006-07
10 further recorded trials
  • NCT00099502
    2007-08
  • NCT00039988
    2007-11
  • NCT00819195
    2012-09
  • NCT00490906
    2012-12
  • NCT00819000
    2013-01
  • NCT02753088
    2015-11
  • NCT03315923
    2019-03-01
  • NCT04928313
    2020-02-17
  • NCT06003972
    2023-03-12
  • NCT03209479
    2024-03-31

At the median, Glatiramer Acetate's trials enrolled 138.5 people — anything larger?

Median enrolment
138.5
Largest enrolment
3526
Registered trials counted
66

What do 8973 spontaneous reports say about Glatiramer Acetate — and not say?

These are reports people sent to a regulator. They do not show the medicine caused the reaction. Nobody counted how many people took the medicine and reported nothing. The same event can be reported more than once, and many reports are incomplete. News coverage, lawsuits and new warnings change how often people report. A count is not a rate and not a risk.

Glatiramer Acetate appears in spontaneous reports to regulators. Across the 10 most-reported reaction terms, 8973 reaction mentions were counted: injection site reaction 1584; injection site pain 1379; multiple sclerosis relapse 1309; injection site erythema 963. FAERS via Open Targets · CHEMBL1201507 · 2026-06-24

Show the evidence
  • injection site reaction
    1584
  • injection site pain
    1379
  • multiple sclerosis relapse
    1309
  • injection site erythema
    963
  • fall
    950
  • injection site swelling
    605
4 more recorded rows
  • injection site mass
    574
  • urticaria
    561
  • flushing
    524
  • injection site pruritus
    524

recorded 2026-06-24 · last checked 2026-09-04

Which 10 reactions does Glatiramer Acetate's label not list?

fall, flushing and injection site erythema and 7 more reported for Glatiramer Acetate, absent from its label. FAERS via Open Targets · CHEMBL1201507 · 2026-06-24

2 label terms; 10 reported and unlisted; 028fdf0e-2340-407b-bcd8-5a99accdddbf

Show the evidence
  • fall
    count not stated
  • flushing
    count not stated
  • injection site erythema
    count not stated
  • injection site mass
    count not stated
  • injection site pain
    count not stated
  • injection site pruritus
    count not stated
4 more recorded rows
  • injection site reaction
    count not stated
  • injection site swelling
    count not stated
  • multiple sclerosis relapse
    count not stated
  • urticaria
    count not stated

recorded 2026-06-24 · last checked 2026-09-04

Where it is registered
Identifiers, relations and other names

The exact record

ChEMBL id
CHEMBL1201507
CAS number
147245-92-9
RxCUI
84375
Also called
Glatiramer
Development code
COP-1, COPOLYMER-1
Trade name
Copaxone, Glatopa, Glatopa / Copaxone
Also called
ga, ga depot, ga40, ALA:GLU:LYS:TYR=0.427:0.141:0.338:0.095 MW=4700-11000 DALTONS, GLATIRAMER ACETATE [JAN], GLATIRAMER ACETATE [MART.], GLATIRAMER ACETATE [MI], GLATIRAMER ACETATE [ORANGE BOOK], GLATIRAMER ACETATE [USAN], GLATIRAMER ACETATE [VANDF], Glatiramer acetate [WHO-DD]
Salt form
GLATIRAMER ACETATE INJECTION
Component
Glatiramer
Sources (6)

Sources

ChEMBL 37 — CC BY-SA 3.0 Unported · ChEMBL ATC CC BY-SA · ClinicalTrials.gov — US Government work · Open Targets 26.06 — CC0 · mixed register set; per-register licences in docs/specs/corpus-20k-sources.md · openFDA / DailyMed — US Government work

How these records are assembled · Which registers were checked

Index-quality checks
  • identity passed: no open identity hold
  • required summary fields resolved: 4 required field(s) not terminal: Why people use it, Best-supported result, Biggest unanswered question, Human evidence
  • public claims reviewed: 0 reviewed claim(s); drafts are never rendered
  • source coverage passed: 6 source rows
  • no critical contamination: no quarantine open
  • canonical metadata passed: slug and display name present
  • no raw internal fields: enforced by the copy-contract test over the rendered page

This is a record of evidence. It is not medical advice, and it does not say this substance suits you. Nothing here says any substance on RNAWiki is appropriate for a child.